Clinical efficacy of therapy with recombinant human interferon α1b in Hand, Foot, and Mouth Disease with enterovirus 71 infection

Xueyong Huang, Xi Zhang, Fang Wang, Haiyan Wei, Hong Ma, Meili Sui, Jie Lu, Huaili Wang, J. Stephen Dumler, Guangyao Sheng, Bianli Xu Xu

Research output: Contribution to journalArticle

Abstract

A rapid expansion of HFMD with enterovirus 71 infection outbreaks has occurred and caused deaths in recent years in China, but no vaccine or antiviral drug is currently available for EV71 infection. This study aims to provide treatment programs for HFMD patients. We conducted a randomized, double-blind, controlled trial and evaluated clinical efficacy of therapy with rHuIFN-α1b in HFMD patients with EV71 infection. There were statistical differences in outcomes including the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load of the HFMD patients among ultrasonic aerosol inhalation group, intramuscular injection group and control group. rHuIFN-α1b therapy reduced the fever clearance time, healing time of typical skin or oral mucosa lesions, and EV71 viral load in children with HFMD.

Original languageEnglish (US)
Article numbere0148907
JournalPLoS One
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Clinical efficacy of therapy with recombinant human interferon α1b in Hand, Foot, and Mouth Disease with enterovirus 71 infection'. Together they form a unique fingerprint.

  • Cite this

    Huang, X., Zhang, X., Wang, F., Wei, H., Ma, H., Sui, M., Lu, J., Wang, H., Dumler, J. S., Sheng, G., & Xu, B. X. (2016). Clinical efficacy of therapy with recombinant human interferon α1b in Hand, Foot, and Mouth Disease with enterovirus 71 infection. PLoS One, 11(2), [e0148907]. https://doi.org/10.1371/journal.pone.0148907